research use only
Cat.No.S3998
| Related Targets | HDAC Antioxidant ROS IκB/IKK Nrf2 AP-1 MALT NOD |
|---|---|
| Other NF-κB Inhibitors | DCZ0415 Omaveloxolone (RTA-408) BAY 11-7082 (BAY 11-7821) JSH-23 QNZ (EVP4593) Caffeic Acid Phenethyl Ester SC75741 DHA (Dihydroartemisinin) Andrographolide CBL0137 |
|
In vitro |
DMSO
: 125 mg/mL
(605.82 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 206.33 | Formula | C8H14O2S2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1200-22-2 | -- | Storage of Stock Solutions |
|
|
| Synonyms | (R)-(+)-α-Lipoic acid, α-Lipoic acid, Alpha-Lipoic acid | SMILES | C1CSSC1CCCCC(=O)O | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
NF-κB
LTR
LTR
|
|---|---|
| In vitro |
Using L6 myotubes and 3T3-L1 adipocytes as a model of muscle and fat cells in culture, (+)-α-Lipoic acid (R-LA) is shown to increase tyrosine phosphorylation of insulin receptor and IRS-1, to enhance PI 3-kinase and Akt1 activities, to elevate GLUT4 content in the plasma membranes, and to increase glucose uptake into the cells. 3T3-L1 adipocytes possess a low capacity to reduce this compound and the oxidized isoforms are effective in stimulating glucose transport. This chemical modulates glucose transport by changing intracellular redox status. Insulin receptor is a target of this compound action. |
References |
|
(data from https://clinicaltrials.gov, updated on 2026-08-05)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07725484 | NOT_YET_RECRUITING | Heart Failure Due to Coronary Artery Disease |
Shanghai Zhongshan Hospital |
2026-11-01 | PHASE3 |
| NCT05713799 | NOT_YET_RECRUITING | Insulin Resistance; Obesity |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2026-09-09 | PHASE2 |
| NCT07685431 | RECRUITING | Female Infertility Due to Diminished Ovarian Reserve |
Kaohsiung Veterans General Hospital. |
2026-06-11 | |
| NCT06286098 | ENROLLING_BY_INVITATION | Hemodialysis Complication; Pediatric Kidney Disease; Cardiovascular Complication |
Ain Shams University |
2025-02-02 | PHASE3 |
| NCT07785544 | NOT_YET_RECRUITING | Painful Diabetic Peripheral Neuropathy |
Bangladesh Medical University |
2026-08-25 | |
| NCT07501663 | RECRUITING | Peripheral Neuropathy |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2026-01-20 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.